Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Deferred Tax: 2014-2021

Historic Long-Term Deferred Tax for Enanta Pharmaceuticals (ENTA) over the last 7 years, with Jun 2021 value amounting to $345,000.

  • Enanta Pharmaceuticals' Long-Term Deferred Tax fell 97.74% to $345,000 in Q2 2021 from the same period last year, while for Jun 2021 it was $345,000, marking a year-over-year decrease of 97.74%. This contributed to the annual value of $345,000 for FY2020, which is 96.96% down from last year.
  • As of Q2 2021, Enanta Pharmaceuticals' Long-Term Deferred Tax stood at $345,000, which was down 0.00% from $345,000 recorded in Q1 2021.
  • Over the past 5 years, Enanta Pharmaceuticals' Long-Term Deferred Tax peaked at $17.7 million during Q2 2017, and registered a low of $345,000 during Q3 2020.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $9.6 million (2019), whereas its average is $7.0 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Long-Term Deferred Tax surged by 203.32% in 2017, and later slumped by 97.74% in 2021.
  • Enanta Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at $7.6 million in 2017, then rose by 22.20% to $9.2 million in 2018, then climbed by 15.22% to $10.7 million in 2019, then crashed by 96.76% to $345,000 in 2020, then crashed by 97.74% to $345,000 in 2021.
  • Its Long-Term Deferred Tax was $345,000 in Q2 2021, compared to $345,000 in Q1 2021 and $345,000 in Q4 2020.